Internet Archive Scholar

Worse prognosis in breast cancer patients can be predicted by immunohistochemical analysis of positive MMP-2 and negative estrogen and progesterone receptors

Edneia A. S. Ramos, Camila T. da Silva, Graciele C. M. Manica, Isabela T. Pereira, Liliane M. B. Klassen, Enilze M. S. F. Ribeiro, Iglenir J. Cavalli, Karin Braun-Prado, Rubens S. Lima, Cicero A. Urban, Fabrício F. Costa, Lucia de Noronha (+1 others)
2016 Revista da Associação Médica Brasileira  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (3.4 MB)
https://web.archive.org/web/20180724174949/http://www.scielo.br/pdf/ramb/v62n8/0104-4230-ramb-62-08-0774.pdf

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL. The file type is application/pdf.

Introduction: Breast cancer is the most cause of death, and approximately 90% of these deaths are due to metastases. Matrix metalloproteinase-2 (MMP-2) gelatinase activity is able to degrade a major constituent of the tumor microenvironment, type IV collagen. Two well-established proteins used as markers in clinical practice for breast cancer are the receptors for estrogen (ER) and progesterone (PR). Although the presence of these receptors has been associated with a better prognosis, loss of
more » ... ese proteins can occur during tumor progression, with subsequent resistance to hormone therapy. Objective: To study the correlation among MMP-2, ER, and PR, as well as the establishment of the metastatic process in primary breast tumors. Method: Breast cancer samples (n=44) were analyzed by immunohistochemistry for MMP-2, ER, and PR. Results: We observed that 90% of patients who had metastases and died showed positive staining for MMP-2 (p=0.0082 for both). Using Kaplan-Meier analysis, we found that negative ER patients who were also positive for MMP-2 had even worse disease-free survival (DFS) and overall survival (OS) (p= 0.012 and p=0.005, respectively). Similar results were found in PR-negative patients for DFS (a trend p=0.077) and OS (p=0.038). Conclusion: Regardless of our small sample size (n=44), the data obtained strongly suggest that MMP-2 in combination with already well-established markers could help to predict the emergence of metastases and death in patients with breast cancer.
doi:10.1590/1806-9282.62.08.774 pmid:27992019 fatcat:mg256xccpzfjdjibradobub57i
DOAJ SciELO
Citation

Edneia A. S. Ramos, Camila T. da Silva, Graciele C. M. Manica, Isabela T. Pereira, Liliane M. B. Klassen, Enilze M. S. F. Ribeiro, Iglenir J. Cavalli, Karin Braun-Prado, Rubens S. Lima, Cicero A. Urban, Fabrício F. Costa, Lucia de Noronha, Giseli Klassen. "Worse prognosis in breast cancer patients can be predicted by immunohistochemical analysis of positive MMP-2 and negative estrogen and progesterone receptors." Revista da Associação Médica Brasileira 62.8 (2016) 774-781